>>Ahead Of The Bell (New York, NY) -- The opening bell rings this morning after stocks closed mixed on Wall Street. This comes as the post-election rally cooled down on Wednesday as investors mulled over a key inflation report. Last month's consumer price index showed inflation accelerated, right in line with expectations. Investors today will be keeping a look out for the producer price index, along with weekly jobless claim. At yesterday's closing bell, the Dow Jones Industrial Average gained 47 points to 43-958. The S&P 500 gained one point to 59-85. The Nasdaq dropped by 19 points to 19-230.
>>Polymarket CEO's Home Reportedly Raided By FBI
(New York, NY) -- Betting platform Polymarket is calling an FBI raid on its CEO's home "obvious political retribution" for predicting Donald Trump's election victory. The FBI reportedly raided the Manhattan home of CEO Shayne Coplan Wednesday, seizing his phone and other electronic devices. The Justice Department is investigating the company for allegedly allowing U.S.-based customers to make trades on the platform in violation of restrictions. A spokesman for the company suggested it was because of correctly calling the election for Trump.
>>Meta To Face Trial In Antitrust Case Brought By FTC
(Menlo Park, CA) -- Meta will face trial in an antitrust case brought by the FTC over its acquisitions of Instagram and WhatsApp. A federal judge issued an order denying the Mark Zuckerberg-led company's request to drop the case. The FTC sued Meta in 2020, accusing the social media giant of having an illegal monopoly on social networking. Meta has denied those allegations and said it would review the judge's opinion when filed.
>>JPL Lays Off Hundreds Of Workers
(Pasadena, CA) -- NASA's Jet Propulsion Laboratory in Pasadena, California is laying off workers for the second time this year. An estimated 325 employees were let go on Wednesday. That's about five percent of JPL's workforce.
>>23andMe Announces Layoffs
(South San Francisco, CA) -- Genetic testing company 23andMe says it's cutting 40 percent of its workforce. That's about 200 jobs. The company on Tuesday warned that it has "substantial doubt" about its ability to keep operating. The company's share price has fallen 70 percent this year and is considering licensing or selling therapies it has developed using its collected genetic information.
